Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19.

Naik, Rajashri R; Shakya, Ashok K; Aladwan, Safwan M; El-Tanani, Mohamed

Naik, Rajashri R; Shakya, Ashok K; Aladwan, Safwan M; El-Tanani, Mohamed.

Afiliação

Naik RR; Department of Biopharmaceutics and Clinical Pharmacy, Al-Ahliyya Amman University, Faculty of Pharmacy, Amman, Jordan.
Shakya AK; Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan.
Aladwan SM; Faculty of Pharmacy, Pharmacological and Diagnostic Research Centre, Al-Ahliyya Amman University, Amman, Jordan.
El-Tanani M; Department of Pharmaceutical Sciences, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.

Front Pharmacol ; 13: 806568, 2022.

Article em En | MEDLINE | ID: mdl-35444538

Palavras-chave

ABL and SRC kinase inhibitors; CDK inhibitors; COVID-19; EGFR inhibitiors; NAK and AXL kinase inhibitor; repurposing agents; tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Jordânia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Jordânia